Year 2019 / Volume 111 / Number 10
Editorial
Shadows in the current management of hepatocellular carcinoma in Spain - An embarrassing truth

727-730

DOI: 10.17235/reed.2019.6594/2019

Javier Crespo, Raúl J. Andrade,

Abstract
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related deaths worldwide. Up to 80% of patients with HCC have concomitant cirrhosis as a result of hepatitis B or C virus, alcohol abuse, or non-alcoholic steatohepatitis.
Share Button
New comment
Comments

21/10/2019 18:17:08
Editorial que confunde términos. levantinib y cabozatinib NO son suceptibles de uso fuera de ficha porque SI tienen indicación. Regorafenib tiene Una resolución n expresa de NO financiacion, por ello no puede utilizarse en ningún hospital de la red pública.No se trata de financiar o no. EL ministerio ya negoció ,con el laboratorio y no consiguió un acuerdo, no se trata de háganlo ya para q yo pueda, se trata de q el lab proponga precio que se considere apropiado.
resoluciones. Expresa de no financiación significa NO se puede utilizar puesto que Existe Una resolución n negativa (ver informe de la abogacía del estado)


References
1. Ju Dong Yang, et al A global view of hepatocellular carcinoma: trends, risk, prevention and management, Nature Reviews Gastroenterology & Hepatology (2019
2. Llovet, et al. Nat Rev Dis Prim 2016; 2: 16018
3. Varela M, Reig M, De la Mata M, et al. Tratamiento del carcinoma hepatocelular en España. Análisis de los 705 casos en 62 centros. Med Clin (Barc). 2010; 134(13): 560-576.
4. Rodríguez de Lope C, Reig M, Matilla A, et al. Grupo de Estudio de Cáncer Hepático (GECH). Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. Med Clin (Barc). 2017 Jul 21;149(2):61-71.
5. González de Frutos C, Marín Serrano E, Gómez Rubio M, et al.
Formación en ecografía de los médicos residentes de aparato digestivo: encuesta y proyecto docente de la Asociación Española de Ecografía Digestiva. Rev Esp Enferm Dig 2019;111(10):xxx-xxx
6. Llovet JM, Ricci S, Mazzaferro V, t al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
7. Qin S, Han KH, Ikeda K, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
8. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial; RESORCE Investigators. Lancet. 2017 Jan 7;389(10064):56-66.
9. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018 Jul 5;379(1):54- 63.
10. Zhu AX, Park JO, Ryoo BY, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first- line therapy with sorafenib (REACH): A randomized, double-blind multicenter, phase 3 trial. REACH Trial Investigators. Lancet Oncol. 2015 Jul;16(7):859-70.
Related articles

Editorial

Hemophilia and hepatology, back to the future

DOI: 10.17235/reed.2024.10105/2023

Digestive Diseases Image

Giant cystic hepatocarcinoma in the absence of cirrhosis

DOI: 10.17235/reed.2021.8313/2021

Letter

Biopsy for hepatocellular carcinoma: only occasionally

DOI: 10.17235/reed.2020.6935/2020

Letter

Hepatocarcinoma diagnosis. Reflection is required

DOI: 10.17235/reed.2020.6845/2019

Letter

Rhabdomyolysis in a patient under treatment with sorafenib

DOI: 10.17235/reed.2020.6440/2019

Case Report

Ectopic hepatocellular carcinoma arising from the peritoneum

DOI: 10.17235/reed.2019.6408/2019

Digestive Diseases Image

Debut of an unusual liver cirrhosis

Review

New challenges in clinical research on hepatocellular carcinoma

DOI: 10.17235/reed.2015.4012/2015

Citation tools
Crespo J, Andrade R. Shadows in the current management of hepatocellular carcinoma in Spain - An embarrassing truth. 6594/2019


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1167 visits.
This article has been downloaded 634 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 29/08/2019

Accepted: 01/09/2019

Online First: 25/09/2019

Published: 03/10/2019

Article Online First time: 27 days

Article editing time: 35 days


Share
This article has been rated by 2 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology